Venlafaxine Hydrochloride
PreclinicalSmall molecule
TevaVenlafaxine Hydrochloride is one of 60 small molecule programs targeting Aphasia. It is currently in Preclinical.
2
Indications
8
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Elavil
AstraZenecaPhase 3
Daliresp
AstraZenecaPhase 3
Crestor
AstraZenecaPhase 3
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions1 trial
Head and Neck Cancer1 trial
Major Depressive Disorder1 trial
3 more indications
AIN1 trial
Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers
Unknown status·—·N/A·NCT04229602·28 enrolled
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Venlafaxine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]